< Back to previous page

Patent

Lassavirus vaccines

The present invention relates to polynucleotides comprising a sequence of a live, infectious, attenuated Flavivirus wherein a nucleotide sequence encoding at least a part of a arenavirus glycoprotein protein is located at the intergenic region between the E and NS1 gene of said Flavivirus, such that a chimeric virus is expressed, characterised in that the encoded sequence C terminally of the E protein of said Flavivirus and N terminally of the signal peptide of the NS1 protein of said Flavivirus comprises in the following order: - a further signal peptide of a Flavivirus NS1 protein, -an arenavirus Glycoprotein protein lacking the N terminal signal sequence and the GP2 transmembrane domain, - a TM1 and TM2 domain of a flaviviral E protein.
Patent Publication Number: WO2021048402
Year filing: 2021
Year approval: 2022
Year publication: 2021
Status: Requested
Technology domains: Pharmaceuticals
Validated for IOF-key: Yes
Attributed to: Associatie KULeuven